Stock DNA
Pharmaceuticals & Biotechnology
USD 135 Million (Micro Cap)
17.00
NA
0.00%
1.04
-999,999.00%
3.23
Revenue and Profits:
Net Sales:
26 Million
(Quarterly Results - Dec 2025)
Net Profit:
2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-43.89%
0%
-43.89%
6 Months
-48.28%
0%
-48.28%
1 Year
-30.0%
0%
-30.0%
2 Years
-67.72%
0%
-67.72%
3 Years
-45.18%
0%
-45.18%
4 Years
-12.94%
0%
-12.94%
5 Years
-71.83%
0%
-71.83%
FitLife Brands, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
29.33%
EBIT Growth (5y)
33.79%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.76%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
3.23
EV to EBIT
14.21
EV to EBITDA
14.00
EV to Capital Employed
2.09
EV to Sales
2.53
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
14.73%
ROE (Latest)
19.04%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 9 Schemes (6.22%)
Foreign Institutions
Held by 13 Foreign Institutions (0.73%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
25.90
23.50
10.21%
Operating Profit (PBDIT) excl Other Income
2.70
3.30
-18.18%
Interest
0.80
0.60
33.33%
Exceptional Items
-0.20
-0.80
75.00%
Consolidate Net Profit
1.60
0.90
77.78%
Operating Profit Margin (Excl OI)
96.30%
133.60%
-3.73%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 10.21% vs 45.96% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 77.78% vs -47.06% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
81.50
64.50
26.36%
Operating Profit (PBDIT) excl Other Income
12.60
13.50
-6.67%
Interest
1.90
1.40
35.71%
Exceptional Items
-2.10
-0.30
-600.00%
Consolidate Net Profit
6.30
9.00
-30.00%
Operating Profit Margin (Excl OI)
149.00%
207.40%
-5.84%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 26.36% vs 22.39% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -30.00% vs 69.81% in Dec 2024






